RESUMEN
The MYC family of oncogenes encodes a set of three related transcription factors that are overexpressed in many human tumors and contribute to the cancer-related deaths of more than 70,000 Americans every year. MYC proteins drive tumorigenesis by interacting with co-factors that enable them to regulate the expression of thousands of genes linked to cell growth, proliferation, metabolism and genome stability. One effective way to identify critical co-factors required for MYC function has been to focus on sequence motifs within MYC that are conserved throughout evolution, on the assumption that their conservation is driven by protein-protein interactions that are vital for MYC activity. In addition to their DNA-binding domains, MYC proteins carry five regions of high sequence conservation known as Myc boxes (Mb). To date, four of the Mb motifs (MbI, MbII, MbIIIa and MbIIIb) have had a molecular function assigned to them, but the precise role of the remaining Mb, MbIV, and the reason for its preservation in vertebrate Myc proteins, is unknown. Here, we show that MbIV is required for the association of MYC with the abundant transcriptional coregulator host cell factor-1 (HCF-1). We show that the invariant core of MbIV resembles the tetrapeptide HCF-binding motif (HBM) found in many HCF-interaction partners, and demonstrate that MYC interacts with HCF-1 in a manner indistinguishable from the prototypical HBM-containing protein VP16. Finally, we show that rationalized point mutations in MYC that disrupt interaction with HCF-1 attenuate the ability of MYC to drive tumorigenesis in mice. Together, these data expose a molecular function for MbIV and indicate that HCF-1 is an important co-factor for MYC.
Asunto(s)
Secuencias de Aminoácidos/genética , Transformación Celular Neoplásica/genética , Factor C1 de la Célula Huésped/genética , Mutación , Proteínas Proto-Oncogénicas c-myc/genética , Secuencia de Aminoácidos , Animales , Sitios de Unión/genética , Secuencia Conservada/genética , Evolución Molecular , Células HEK293 , Factor C1 de la Célula Huésped/metabolismo , Humanos , Inmunoprecipitación , Ratones , Células 3T3 NIH , Unión Proteica , Proteínas Proto-Oncogénicas c-myc/metabolismo , Homología de Secuencia de AminoácidoRESUMEN
The relevance of changes to the coding sequence of the c-MYC oncogene to malignancy is controversial. Overexpression of a pristine form of MYC is observed in many cancers and is sufficient to drive tumorigenesis in most contexts. Yet missense changes to MYC are found in ~50% of Burkitt's lymphomas, aggregate within an amino-terminal degron important for proteasomal destruction of MYC, and where examined profoundly enhance the tumorigenic properties of MYC in vitro and in vivo. Much of the controversy surrounding these mutants stems from the limited number of mutations that have been evaluated and their clustering within a single region of the MYC protein; the highly-conserved Myc box I (MbI) element. Here, by analysis of extant genomic data sets, we identify a previously unrecognized hotspot for tumor-associated MYC mutations, located in a conserved central portion of the protein. We show that, despite their distal location in MYC, mutations in this region precisely phenocopy those in MbI in terms of stability, in vitro transformation, growth-promoting properties, in vivo tumorigenesis and ability to escape p53-dependent tumor surveillance mechanisms. The striking parallels between the behavior of tumor-derived mutations in disparate regions of the MYC protein reveals that a common molecular process is disrupted by these mutations, implying an active role for these mutations in tumorigenesis and suggesting that different therapeutic strategies may be needed for treatment of lymphomas expressing wild type versus mutant forms of MYC protein.
Asunto(s)
Linfoma/genética , Mutación Missense , Proteínas Proto-Oncogénicas c-myc/genética , Proteínas Proto-Oncogénicas c-myc/metabolismo , Secuencia de Aminoácidos , Animales , Línea Celular Tumoral , Secuencia Conservada , ADN/análisis , Humanos , Linfoma/metabolismo , Linfoma/patología , Ratones , Células 3T3 NIHRESUMEN
Interleukin-18 (IL-18) is a pro-inflammatory cytokine involved in the Th1 immune response and expressed by a variety of cell types. IL-18 is a member of the IL-1 family and plays an important role in autoimmune diseases and inflammation. Using reverse transcriptase-polymerase chain reaction (RT-PCR) mRNA expression of IL-18, IL-18 receptor alpha (IL-18R alpha), and beta (IL-18R beta) were studied in tumour derived human B-cell lines. Furthermore, we investigated IL-18 protein secretion by using enzyme linked immunosorbent assay (ELISA). The results, as presented in this report, suggest that IL-18, IL-18R alpha, and IL-18R beta mRNA are constitutively and ubiquitously expressed in human B-cell lines, but secretion of the functional protein does not occur. We therefore speculate that IL-18 possibly affects B-cells through paracrine actions.
Asunto(s)
Linfocitos B/inmunología , Interleucina-18/genética , ARN Mensajero/análisis , Receptores de Interleucina/genética , Línea Celular Tumoral , Humanos , Subunidad alfa del Receptor de Interleucina-18 , Receptores de Interleucina-18 , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The interaction of human T-cell lymphotropic virus I (HTLV-I) tax gene with host cell factors plays an important role in the maintenance of the transformed state. There have been numerous reports that have demonstrated the role of tax in transactivating several cytokines. In this study, we show that upon mitogen stimulation, macrophage inflammatory protein-1 beta (MIP-1beta) is expressed and secreted in tax-transfected Jurkat cells. Furthermore, expression of CC-chemokine receptor-5 (CCR5) mRNA in these cells suggests an autocrine role for MIP-1beta in HTLV-I-infected T-cells. These results, coupled with our earlier observations, demonstrate the influence that extracellular Tax protein might have on modulating host chemokines for proliferation and transformation of uninfected cells.
Asunto(s)
Comunicación Autocrina/fisiología , Genes pX , Virus Linfotrópico T Tipo 1 Humano/genética , Proteínas Inflamatorias de Macrófagos/metabolismo , Linfocitos T/metabolismo , Quimiocina CCL4 , Ensayo de Inmunoadsorción Enzimática , Productos del Gen tax/metabolismo , Humanos , Células Jurkat , Activación de Linfocitos , Proteínas Inflamatorias de Macrófagos/genética , Fitohemaglutininas/farmacología , Receptores CCR5/genética , Receptores CCR5/metabolismo , Acetato de Tetradecanoilforbol/farmacología , TransfecciónRESUMEN
Using synthetic inhibitors, it has been shown that the ectopeptidase dipeptidyl peptidase IV (DP IV) (CD26) plays an important role in the activation and proliferation of T lymphocytes. The human immunodeficiency virus-1 Tat protein, as well as the N-terminal nonapeptide Tat(1-9) and other peptides containing the N-terminal sequence XXP, also inhibit DP IV and therefore T cell activation. Studying the effect of amino acid exchanges in the N-terminal three positions of the Tat(1-9) sequence, we found that tryptophan in position 2 strongly improves DP IV inhibition. NMR spectroscopy and molecular modeling show that the effect of Trp(2)-Tat(1-9) could not be explained by significant alterations in the backbone structure and suggest that tryptophan enters favorable interactions with DP IV. Data base searches revealed the thromboxane A2 receptor (TXA2-R) as a membrane protein extracellularly exposing N-terminal MWP. TXA2-R is expressed within the immune system on antigen-presenting cells, namely monocytes. The N-terminal nonapeptide of TXA2-R, TXA2-R(1-9), inhibits DP IV and DNA synthesis and IL-2 production of tetanus toxoid-stimulated peripheral blood mononuclear cells. Moreover, TXA2-R(1-9) induces the production of the immunosuppressive cytokine transforming growth factor-beta1. These data suggest that the N-terminal part of TXA2-R is an endogenous inhibitory ligand of DP IV and may modulate T cell activation via DP IV/CD26 inhibition.
Asunto(s)
Dipeptidil Peptidasa 4/inmunología , Receptores de Tromboxanos/inmunología , Linfocitos T/inmunología , Dipeptidil Peptidasa 4/metabolismo , Regulación hacia Abajo , Productos del Gen tat/inmunología , Productos del Gen tat/metabolismo , Humanos , Ligandos , Activación de Linfocitos , Receptores de Tromboxanos/metabolismo , Transducción de Señal/inmunología , Linfocitos T/metabolismoRESUMEN
The stability of cell associated fluorescence is an essential requirement for measurements of cellular enzymatic activity via enzyme catalyzed liberation of fluorophores. Rhodamine 110 (R110), a highly fluorescent xanthene dye, was used to synthesize nonfluorescent dipeptidyl peptidase IV (DP IV) substrates Xaa-Pro-R110-Y allowing the stable covalent binding of the enzymatically released fluorescent R110-Y on cells. All compounds have been characterized as substrates of isolated DP IV with kcat/Km values of about 10(6) M-1.s-1. The hydrophobicity of the residue Y affects the affinity of the substrate to the catalytic site of DP IV. The compounds are characterized as sensitive substrates of cell surface associated DP IV of DP IV rich U-937 cells. The binding of the enzymatically released R110-Y on cells results in a stable cellular fluorescence. This way, the quantitative determination of cell surface associated DP IV activity is possible.
Asunto(s)
Compuestos Cromogénicos/metabolismo , Dipeptidil Peptidasa 4/metabolismo , Colorantes Fluorescentes/metabolismo , Rodaminas/metabolismo , Aminoácidos/metabolismo , Animales , Dominio Catalítico , Compuestos Cromogénicos/química , Dipeptidil Peptidasa 4/análisis , Células Epiteliales/enzimología , Colorantes Fluorescentes/química , Fluorometría , Humanos , Riñón/enzimología , Cinética , Proteínas de Neoplasias/análisis , Proteínas de Neoplasias/metabolismo , Prolina/química , Especificidad por Sustrato , Porcinos , Células U937/enzimologíaRESUMEN
In addition to solamargine, isoanguivine and solasonine, two new steroid alkaloid glycosides, xylosylsolamargine and xylosyl-beta-solamarine, have been isolated from the aerial parts of Solanum coccineum, the structures of which have been elucidated as (25R)-3 beta-[O-beta-D-xylopyranosyl-(1-->2)-O-alpha-L-rhamnopyranosyl- (1-->4)-O-[alpha-L-rhamnopyranosyl-(1-->2)]-beta-D-glucopyranosyloxy+ ++]-22 alpha N-spirosol-5-ene and (25S)-3 beta-[O-beta-D-xylopyranosyl-(1-->2)-O-alpha-L-rhamnopyranosyl- (1-->4)-O-[alpha-L-rhamnopyranosyl-(1-->2)]-beta-D-glucopyranosyloxy+ ++]-22 beta N-spirosol-5-ene.